Canada markets closed

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.1300+0.0100 (+8.33%)
At close: 03:59PM EDT
Full screen
Previous Close0.1200
Open0.1250
Bid0.1250 x 0
Ask0.1300 x 0
Day's Range0.1200 - 0.1300
52 Week Range0.1000 - 0.2700
Volume1,319,678
Avg. Volume236,950
Market Cap56.125M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-0.0190
Earnings DateMay 13, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
  • Baystreet

    Stocks in play: ProMIS Neurosciences Inc.

    Announced that it has filed a registration statement on Form 10 with the United States Securities and ...

  • GlobeNewswire

    ProMIS Neurosciences Announces Debt Amendment and Conversion

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, is pleased to announce that it has entered into debenture amendments with seven (7) creditors to settle an aggregate of US$7,000,000

  • GlobeNewswire

    ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has amended its articles to authorize the issuance of 70,000,000 Series 1 Preferred Shares (“Series 1 Shares”